BofA Lowers CRISPR Therapeutics Price Target
On January 22, 2026, BofA analyst Alec Stranahan lowered CRISPR Therapeutics' (NASDAQ:CRSP) price objective from $90 to $89 while retaining a buy rating, modestly trimming 2026 Casgevy projections. CRISPR on January 12, 2026 outlined 2026 milestones including Casgevy pediatric regulatory submissions in H1 2026, Lp(a) and CTX310 progress, Phase 2 CTX611 top-line data in H2 2026, and CTX460/CTX340 trial starts. These updates signal continued commercialization and clinical development momentum.
Key Points
- 1Reports lower price objective for CRSP from $90 to $89, buy rating retained
- 2Notes modest Casgevy projection cuts but projects sequential improvement through 2026 for the program
- 3Lists 2026 milestones (pediatric filings, Lp(a), CTX310, CTX611, CTX460/340) guiding development plans
Scoring Rationale
Moderate industry relevance with official guidance and analyst support, limited novelty and low relevance to core AI/ML topics.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
